Journal
NEPHROLOGY DIALYSIS TRANSPLANTATION
Volume 34, Issue 8, Pages 1272-1279Publisher
OXFORD UNIV PRESS
DOI: 10.1093/ndt/gfz131
Keywords
Alport; autosomal; therapy; treatment; X linked
Categories
Funding
- ISCIII: RETIC REDINREN [RD16/0009]
- FIS FEDER FUNDS [PI15/01824, PI18/00362]
- Catalan Government [AGAUR 2014/SGR-1441]
Ask authors/readers for more resources
Alport syndrome (AS) is the most frequent inherited kidney disease after autosomal dominant polycystic kidney disease. It has three different patterns of inheritance-autosomal dominant, autosomal recessive and X-linked-which in part explains the wide spectrum of disease, ranging from isolated microhae-maturia to end-stage renal disease early in life. The search for a treatment for AS is being pursued vigorously, not only because of the obvious unmet need but also because AS is a rare disease and any drug approved will have an orphan drug designation with its various benefits. Moreover, AS patients are quite young with very few comorbidities, which facilitates clinical trials. This review identifies the particularities of each pattern of inheritance but focuses mainly on new drugs or therapeutic targets for the disease. Most treatment-related investigations are directed not at the main abnormality in AS, namely collagen IV composition, but rather at the associated inflammation and fibrosis. Thus, AS may serve as a proof of concept for numerous drugs of potential value inmany diseases that cause chronic kidney disease.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available